
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC
Link to published version (if available):
10.2174/1874192401711010001

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Bentham Open at https://benthamopen.com/Abstract/TOCMJ-11-1. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Hypoxic Pulmonary Vasoconstriction in Humans: Tale or Myth

A. Hussain1,*, M.S. Suleiman2, S.J. George2, M. Loubani1 and A. Morice3

1Department of Cardiothoracic Surgery, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ, UK
2School of Clinical Sciences, Bristol Royal Infirmary, Marlborough Street, Bristol, BS2 8HW, UK
3Department of Respiratory Medicine, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ, UK

Received: October 13, 2016 Revised: December 02, 2016 Accepted: December 09, 2016

Abstract: Hypoxic Pulmonary vasoconstriction (HPV) describes the physiological adaptive process of lungs to preserves systemic oxygenation. It has clinical implications in the development of pulmonary hypertension which impacts on outcomes of patients undergoing cardiothoracic surgery. This review examines both acute and chronic hypoxic vasoconstriction focusing on the distinct clinical implications and highlights the role of calcium and mitochondria in acute versus the role of reactive oxygen species and Rho GTPases in chronic HPV. Furthermore it identifies gaps of knowledge and need for further research in humans to clearly define this phenomenon and the underlying mechanism.

Keywords: Hypoxic Pulmonary Vasoconstriction, Human, Acute hypoxia, Chronic hypoxia, Pulmonary hypertension.

INTRODUCTION

Hypoxic Pulmonary Vasoconstriction (HPV) is a fundamental physiological mechanism to redirect the blood from poorly to better-aerated areas of lungs to optimize the ventilation perfusion matching [1]. Persistent hypoxia results in increased pulmonary vascular resistance and right ventricular afterload, which leads to hypoxic pulmonary hypertension (HPH) [2]. HPV was initially thought to be caused by alveolar hypoxia by means of local lung mechanism but recent advances suggest that pulmonary artery smooth muscle cells (PASMC) constitute both the sensor and the transducer of the hypoxic signal as well as its contractile effector [3]. A series of experiments performed to explain the HPV on macroscopic and microscopic level has been reported although the underlying mechanism is not clear [4, 5]. However, vast majority of experiments are performed in animals with little data available from humans. Experiments performed on animals are highly dependent on the species studied and therefore generally inapplicable to humans. Therefore new methodologies are needed to understand the human disease biology. In this review we concentrate on the existing evidence for HPV within humans and looking at the pulmonary vascular reactivity to acute and chronic hypoxia and the role of endothelium in vessels size in HPV.

1. OVERVIEW OF THE PULMONARY CIRCULATION

Pulmonary circulation is the segment of cardiovascular system, which carries the blood to and from the lungs. Its primary function is to oxygenate the deoxygenated blood that has returned to the right side of the heart. The oxygenated (oxygen-rich) blood is then delivered to the left side of heart and thus the systemic circulation [6, 7] (Fig. 1).

1.1. Anatomy of Pulmonary Circulation

The vascular wall is made up of three layers; tunica intima (internal layer), tunica media (middle layer) and tunica externa (outer layer) [8, 9]. Endothelial cells are located in the intima and play an important role in regulating vascular...
function by responding to neurotransmitters, hormones and vasoactive factors [10]. The endothelium and smooth muscle are the vital components for maintenance of arterial tone and regulation of blood pressure. The main purpose of the arteries is to deliver the blood to the organs with high pulse pressure. Arteries can broadly be divided into conducting arteries, conduit arteries (macro-vasculature) and resistance arteries (microvasculature) based on their size, anatomical position and functionality. Conducting arteries are the largest in size and rich in elastic tissues which support the vessels to expand and recoil to accommodate high changes in blood pressure and volume. The aorta, pulmonary artery and carotid arteries are the main examples of conducting arteries [11].

Fig. (1). Schematic representation of pulmonary circulation. Red shows oxygen-rich CO₂-poor blood. Blue shows oxygen-poor CO₂-rich blood.

Pulmonary arteries in particular are less muscular, more distensible and compressible compared to their systemic counterpart and resistance pulmonary arterioles contain the most smooth muscle in the pulmonary vasculature [12, 13]. Bronchial circulation is a part of systemic circulation that provides nourishment to the lungs [14]. Pulmonary arteries unlike systemic arteries are always hypoxic as they conduct relatively deoxygenated blood and the gas exchange occurs at capillary level where lungs excrete carbon dioxide [15, 16].

1.2. Regulation of Pulmonary Circulation

Right ventricle and left ventricles are connected in series as is the case for the pulmonary and systemic circulation [17]. The pulmonary circulatory flow is dependent on systemic blood coming to it through right heart as well as the afterload that is determined by the aortic pressure and systemic vascular resistance [18, 19]. In addition to this the pulmonary circulation is also influenced by alveolar compression, gravity, body position and lung volume [20].

The regional ventilation and distribution of blood flow in lung varies from the apex to the base in the upright
position [21]. At the apex of the lung the alveolar pressure is higher than the pulmonary artery pressure that results in wasted ventilation. On contrary at the base, the pulmonary pressure is higher than alveolar pressure that causes wasted perfusion [22, 23]. This difference in matching of blood flow to ventilation determines the regional blood flow and disrupts the gas exchange [24, 25].

At tissue level the release or inhibition of certain factors control regional pulmonary blood flow [26]. Agonists of smooth muscle contraction such as endothelin increase the pulmonary artery tone [27, 28]. Nitric oxide and acetylcholine are smooth muscle relaxants that are known factors to decrease the pulmonary artery tone [29 - 31].

The pulmonary circulation is a low pressure, low resistance and high flow circuit and depending on age the average resistance is between 1 – 2.5 mmHg.min.L\(^{-1}\) [32]. Unlike systemic arterioles that dilate in response to hypoxia, the pulmonary arterioles and venules constrict when exposed to hypoxia [33]. This phenomenon is known as hypoxic pulmonary vasoconstriction that causes diversion of pulmonary blood from poorly ventilated to well-oxygenated areas of lungs to preserve systemic oxygenation [34]. This vasoconstrictive response of HPASMc to hypoxia is further augmented when pulmonary vasculature exposed to hypercapnia and the combined hypoxic and hypercapnic effects are additive not synergistic [35].

However if this short term beneficial role of HPV to facilitate perfusion and ventilation persist or alveolar hypoxia become more widespread or if the hypoxic stimulus is not removed as in intrinsic lung disease, this results in increase in pulmonary resistance and subsequent pulmonary hypertension [36, 37].

2. ACUTE HYPOXIC PULMONARY VASOCONSTRICTION

HPV in humans appears to have several components [38], the first acute phase occur within 5 minute with a mean time constant of 151-160 (+/- 24.8-42) sec followed by a plateau phase of at least 20 minutes [39, 40]. A second phase also known as sustained phase start after a latency period of 30 min and plateau at 2 hours [40] followed by a third chronic phase taking upward of 8 hours [38, 41]. During the sustained hypoxic phase an initial temporary vasodilation response is seen followed by secondary vasoconstriction period [42]. The precise underlying mechanism of HPV is still uncertain but cells in the endothelium and/or smooth muscle cells are involved as HPV can be seen in isolated pulmonary artery [43 - 45]. Fishman describes the role of nervous system and humoral agents as modulatory rather than primary cause of HPV [46]. Both adrenergic and cholinergic nerve fibres are found in human lung tissue. \(\alpha\) adrenergic receptors are predominant both functionally and numerically in lungs as compared to \(\beta\) adrenergic receptors [47]. The adrenergic system only contributes to maintain the initial resting tone needed for HPV while the cholinergic system was found to play no role in the control of pulmonary circulation [48, 49]. This concept of little role of nervous system modulatory role is further strengthened by the fact that HPV still persists in transplanted and denervated lungs [50].

2.1. Role of Calcium in Hypoxic Pulmonary Vasoconstriction

Pulmonary artery smooth muscle cells (PASMCs) are found in large arteries as well as in small arterioles [13] and are believed to cause vasoconstriction in response to hypoxia by increasing the intracellular calcium (\(Ca^{2+}\)). Intracellular concentration of \(Ca^{2+}\) is mainly regulated by release of sarcoplasmic reticulum stored \(Ca^{2+}\), extracellular \(Ca^{2+}\) influx through voltage gated \(Ca^{2+}\) channels and receptors or store operated \(Ca^{2+}\) channels [51]. PASMCs membrane potential is regulated by voltage gated \(K^+\) channels, which control the cytoplasmic \(Ca^{2+}\) concentration. Voltage gated \(K^+\) channels cause vasoconstriction when exposed to acute hypoxia by increasing cytoplasmic \(Ca^{2+}\) concentration and may have a role in some of the components of HPV response [52, 53]. Hypoxia depolarizes the membrane by reducing the outward \(K^+\) current and leads to vasoconstriction by increasing the influx of \(Ca^{2+}\) through voltage gated \(Ca^{2+}\) channels.

Michelakis et al. demonstrated that pulmonary artery smooth muscle cells have the ability to sense oxygen and react to hypoxia without any influence from surrounding parenchyma [54]. They also conclude that dissimilarities in systemic and pulmonary circulation response to hypoxia is due to the manifestation of different \(K^+\) channels that trigger hyperpolarization and vasodilation in systemic circulation and depolarization and vasoconstriction in pulmonary circulation.

Tang et al. showed that the increase of calcium in PASMCs after acute hypoxia is due to voltage gated calcium channels to some extent but largely due to transient receptor potential (TRP) channels [55]. TRP channels are cation channels that are present in cellular membranes and involved in various cellular activities e.g. pain, touch, temperature and osmolarity [56, 57]. Channel 6 of Canonical subfamily of TRP (TRPC6) are extensively expressed in HPASMc and on activation by its mediators such as epoxyeicosatrienoic acids (EETs) induced hypoxic pulmonary vasoconstriction
by increasing intracellular Ca\(^{2+}\) [55].

Vanilloid subtype of transient receptor potential channels (TRPV) also act as sensory channels for heat, pain touch and osmotic stress [58]. TRPV channels are present in endothelium, perivascular nerves and vascular smooth muscle cells and its sub-class TRPV4 is expressed highly in pulmonary endothelial cells and human PASMCs [59]. Acute hypoxia increase the EETs levels that activates the TRPV4, as depletions of EETs attenuated the TRPV6 induced HPV [60]. Goldenberg et al. demonstrated that acute hypoxia induced TRPV4 to trigger HPV by increasing Ca\(^{2+}\) influx and phosphorylation of myosin light chain in human PASMCs [61]. EETs activated TRCP6 and TRPV4 work in parallel to each other and form heteromers when exposed to hypoxia, which increase their surface expression and calcium conductance capacity [62, 63].

Meng et al. demonstrated that arachidonic acid [AA] – a membrane phospholipid, attenuates the hypoxia induced rise in intracellular Ca\(^{2+}\) and related vasoconstriction in human PASMCs [64]. Inhibition of endogenous AA production by diacylglycerol, fatty acid hydrolysis and phospholipase A augments pulmonary vasoconstriction and increase intracellular Ca\(^{2+}\) level through TRP channels, voltage gated Ca\(^{2+}\) channel and Na\(^{+}\) - Ca\(^{2+}\) exchanger.

Beside Ca\(^{2+}\) other important mediators such as reactive oxygen species generated during hypoxia. Under normoxic conditions ROS are predominantly produced in mitochondria of pulmonary cells, suggesting that mitochondria might play a role in HPV.

2.2. Role of Mitochondria/Reactive Oxygen Species (ROS) in Hypoxic Pulmonary Vasconstriction

Mitochondria are essential organelle, which contains iron-sulphur complexes, and proteins within the inner mitochondrial membrane that generate energy through electron shuttle called electron transport chain [65]. During oxygen metabolism stable substances like hydrogen peroxide and unstable toxic substances such as hydroxyl and superoxide radicals are produced. These substances are collectively called reactive oxygen species and are produced from I and III complexes of electron transport chain and NADPH oxidase [66]. Mitochondrial electron transport chain is believed to act as an oxygen sensor and facilitates hypoxic induced vascular smooth muscle cells contraction by controlling different kinases and ion channels through ROS [67]. ROS act as an intercellular and intracellular secondary messenger system and reacts with protein residue like cysteine to regulate different signalling pathway [68].

Mehta et al. established that hypoxia attenuates the production of ROS in human PASMCs [65]. These reduce ROS augments pulmonary vasconstriction and subsequent pulmonary hypertension through rise in intracellular Ca\(^{2+}\). In addition to PASMCs, coronary artery smooth muscle cells [CASMCs] also show reduction in ROS production during hypoxia. However these cells dilate instead of constricting and the reason for this differential contractile response is not clear. Wang et al. suggested that this differential response to hypoxia in pulmonary and systemic vasculature might be attributed to the way in which ROS regulate their ion channels [69].

Waypa et al. also showed that hypoxia reduces the mitochondrial production of ROS that results in the hypoxic pulmonary vasoconstriction due to inhibition of voltage gated plasma membrane K\(^{-}\) (K\(_{v}\)) channels [70]. Closure of K\(_{v}\) channels cause membrane depolarization and subsequent vasoconstriction though increases influx of Ca\(^{2+}\).

Freund-Michel et al. described the role of hypoxia induced mitochondrial alterations and mitochondrial dysfunction that shift the oxidative phosphorylation energy production to glycolysis [71]. The resultant hyperpolarized mitochondria reduced the production of ROS and the metabolic shift to increased glycolysis increased the concentration of non-oxidized sugars, lipids and amino acids that are pre requisite to smooth muscle cells proliferation. Similarly Evans et al. proved that inhibition of oxidative phosphorylation in mitochondria through LKB1 (liver kinase B1) – AMPK (amp activated protein kinase) signalling pathway triggers hypoxic pulmonary vasoconstriction [72]. This demonstration of hypoxia induced mitochondrial dysfunction in pulmonary artery endothelium, smooth muscle and adventitia of pulmonary hypertension patients suggests that production of targeted mitochondrial therapies will provide effective therapy for this life threatening disease [73, 74].

In contradiction to the above some studies have shown that hypoxia enhanced the production of ROS instead of reducing it. Perez-Vizcaino et al. demonstrated that pulmonary vascular smooth muscle cells augment the production of ROS particularly hydrogen peroxide when exposed to hypoxia [75]. Hypoxia induced ROS increase the intracellular Ca\(^{2+}\) concentration and PASMCs contraction through modulation of protein kinase C, Rho kinases, ryanodine receptors and voltage gated potassium K\(^{-}\) channels. In addition to vascular mitochondria and NADPH oxidases, ROS are also produced from endothelial nitric oxide synthase (eNOS), arachidonic acid metabolism and xanthine oxidase.
This controversy regarding ROS during hypoxia might be related to the duration of hypoxia. ROS production by human PASMCs attenuates initially when exposed to brief period of hypoxia [65] but increases subsequently [76]. Fig. (2) provides an overview of mechanisms involved in acute hypoxic pulmonary vasoconstriction.

![Mechanism of acute hypoxic vasoconstriction in human pulmonary artery.](image)

**Fig. (2).** Mechanism of acute hypoxic vasoconstriction in human pulmonary artery. ROS= reactive oxygen species, SR= sarcoplasmic reticulum, TRPC=transient receptor potential channels. Redox hypothesis: Hypoxia decreases the ROS level and causes vasoconstriction through inhibition of $K^+$ channels. Energy hypothesis: hypoxia shifts the energy production cycle and produces more AMP that increases the intracellular $Ca^{2+}$ through SR. ROS hypothesis: hypoxia augments the production of ROS that cause HPV through SR induced release of $Ca^{2+}$.

### 3. CHRONIC HYPOXIC PULMONARY VASOCONSTRICTION

Chronic hypoxia is coupled with refractory vasoconstriction and attenuated NO mediated vasodilation that expedites human PASMC medial hypertrophy and subsequent pulmonary hypertension [77]. Production of reactive oxygen species such as hydrogen peroxide and superoxide and hydroxyl radicals in vascular smooth muscle cells is involved in physiological regulation of vascular tone and vascular remodelling [78].

#### 3.1. Role of ROS and Different Ions in Chronic Hypoxic Pulmonary Vasconstriction

Wu et al. demonstrated that chronic hypoxia (PO$_2$ = 30 mmHg for 48 h) cause increased ROS level in PASMCs [76]. This increased ROS production induce a pathophysiological response that cause pulmonary vascular remodelling and subsequent chronic hypoxia associated pulmonary hypertension [79]. Similarly Porter et al. in his experiments showed that hypoxia for more than 72 hours significantly induce the hydrogen peroxide (H$_2$O$_2$) production and proliferation of human pulmonary artery endothelial cells (HPAEC) [80]. The hypoxic induced generation of H$_2$O$_2$ activates the arachidonate 5-lipoxygenase (ALOX 5) pathway that induced HPAEC proliferation and vascular remodelling. Pharmacological blockade of ALOX 5 by zileuton or by MK-886 (inhibitors of 5 lipoxygenase activating protein) attenuates hypoxia-induced proliferation of HPAEC.

Platoshyn et al. showed that chronic hypoxia down regulates the mRNA and protein expression of plasma membrane voltage gated potassium ($K_v$) channels that are responsible for regulation of membrane potential and intracellular $Ca^{2+}$ concentration. The resultant membrane depolarization from inhibition of $K_v$ channels results in amplified $Ca^{2+}$ influx through voltage gated $Ca^{2+}$ channels in PASMCs and mediates pulmonary vasoconstriction and vascular smooth muscle cells proliferation [81]. Zhao et al. demonstrated that the chronic hypoxia leads to the enhanced expression of Zinc transporter ZIP12 in human endothelial and smooth muscle cells [82]. This intracellular rise of Zinc...
plays a role in hypoxia induced pulmonary smooth cells proliferation as inhibition of ZIP12 attenuates HPASMc proliferation and development of pulmonary hypertension. Pharmacological development of ZIP12 inhibitor can be a novel treatment module for pulmonary hypertension management.

3.2. Role of Rho A and Rho B in Chronic Hypoxic Pulmonary Vasoconstriction

Rho GTPases is a family of signalling G Proteins, and are regulators of cytoskeletal dynamics, cell migration, cell polarity, neuronal development, vesicle transport and cytokinesis [83]. Rho-A was the first identified member of Rho GTPases family in 1985 [84].

Rho-A with its downstream factor, Rho Kinase (ROCK) mediated multiple cellular functions such as proliferation, contraction, adhesion, migration and gene expression [85]. Rho-A/ROCK signalling pathway is involved in mediating pulmonary artery hypertension, vasoconstriction and vascular remodelling. Inhibition of Rho-A/Rho kinase pathway by sildenafil (cGMP specific phospho-diesterase inhibitor) proves beneficial in pulmonary hypertension patients due to its vasodilatory effects [86].

Rho-B is a protein homologous to Rho-A and in response to hypoxia induced pulmonary vasoconstriction and vascular remodelling by inducing actin-myosin contractility, enhanced endothelial permeability and promotion of cell growth [87]. Rho-B levels significantly increased in human PASMCs when exposed to hypoxia. PDGF/PDGFR signalling pathway is involved in Rho-B mediated PASMCs proliferation as inhibition of PDGF receptor tyrosine kinase by imatinib attenuates the effects of Rho-B. This shows that Rho-B can be a potential therapeutic target to prevent pulmonary hypertension in humans.

Fig. (3) summarizes the role of ROS and Rho GTPases family in human chronic hypoxic pulmonary vasoconstriction.

Fig. (3). Mechanism of chronic hypoxic vasoconstriction in human pulmonary artery. ROS = reactive oxygen species, Rho A and Rho B are members of Rho GTPases family which is a family of G proteins. Chronic hypoxia induced Rho A and Rho b and ROS production that results in smooth muscle cell proliferation, vascular remodelling and ultimately pulmonary artery hypertension.
4. ROLE OF PULMONARY ARTERY ENDOTHELIUM CELLS IN HYPOXIC PULMONARY VASOCONSTRICTION

Vascular endothelium is a layer of specialized cells between vessel lumen and vascular smooth muscle cells and produces several active compounds including vasodilators and vasoconstrictors [88]. Endothelium derived relaxing factor [EDRF-NO], endothelin, lipooxygenase and cyclooxygenase are endothelial vasoactive agents that regulates vascular tone [89].

4.1. Is Endothelium Necessary for HPV?

Hypoxia induced constriction of human pulmonary artery rings is dependent on endothelium was established by Demiryurek et al. as denuding the endothelium markedly abolish the hypoxic vasoconstriction [44]. In contrary to this Ohe et al. demonstrated that endothelium is not needed for hypoxia-induced vasoconstriction. They established that human pulmonary artery strips [2mm in diameter] constrict in response to hypoxia and removal of endothelium instead of abolishing actually enhanced hypoxia-induced vasoconstriction response [45]. The reason for this controversial response claimed in these studies is not very clear.

4.2. Role of Endothelial Nitric Oxide Synthase (eNOS) in HPV

Endothelial nitric oxide synthase (eNOS) is an enzyme that synthesizes nitric oxide (NO) in vascular endothelium [90]. Nitric oxide regulates cellular proliferation, vascular tone, platelet aggregation and leukocyte adhesion [91].

Takemoto et al. demonstrated that prolonged hypoxia induced endothelial injury and diminished the production of eNOS via Rho kinase (ROCK) induced cytoskeletal changes that results in hypoxia induced pulmonary hypertension [92]. Hypoxia-induced ROCK expression results in decrease in eNOS mRNA and protein production in pulmonary artery endothelial cells. However, Krotova et al. have shown that chronic hypoxia induced NO production in human PAECs and this hypoxia-induced production of NO is further enhanced by inhibition of Arginase II [93]. Similarly Beleslin- Cokic et al. showed that hypoxia stimulates NO production, which is independent of hypoxia-induced reduction of eNOS gene expression [94]. This increase in NO production in response to hypoxia, appears to be the compensatory mechanism of the body by inducing the production of other nitric oxide synthase (NOS) enzymes e.g. iNOS.

Chovanec also demonstrated that the endothelium augment the production of NO and superoxide when exposed to chronic hypoxia [95]. The superoxide with NO facilitates the remodelling of pulmonary vasculature that is characterized by tunica media thickening, augmented muscularity and PASMCs proliferation and migration. Superoxide-NO combination marked the onset of collagen cleavage via peroxynitrite release and the resulted collagen fragments induce pulmonary vessels remodelling.

Ghrelin a peptide hormone produced by ghrelinergic cells in gastrointestinal tract is known to have beneficial effects on human pulmonary artery endothelial cell (HPAECs) function. Yang et al. demonstrated that hypoxia for 24 hours risks the viability of endothelial cells and ghrelin can inhibit hypoxia mediated HPAECs dysfunction by increasing NO production and eNOS phosphorylation [96].

Krotova et al. and Yu et al. demonstrated that human PAECs unlike PASMCs do not proliferate when exposed to chronic hypoxia [93, 97]. This reaction can be due to the fragility of endothelial cells under hypoxic conditions as studies show that hypoxia also increases the permeability of HPAECs [87].

Endothelium seems to play a modularity role in HPV and augments the hypoxic induced HPASMc response by modulating their release of vasoconstrictor and vasodilator factors while PASMc remain the main contractile mechanics as explained by Sylvester [98].

5. EFFECT OF VESSEL SIZE ON PULMONARY VASCULATURE REACTIVITY TO HYPOXIA

The effect of hypoxia on human pulmonary artery strips (HPAs) prepared from human pulmonary artery of diameter < 5 mm was examined by Hoshino et al. and established that the vessels constrict in response to hypoxia [43]. This hypoxia induced contractile response is enhanced when HPAs were pre stimulated with histamine. The response was attenuated by depletion of intracellular and extracellular Ca^{2+} and by HA 1004 – a novel calcium antagonist.

Human pulmonary artery rings - HPARs [2mm in diameter] were demonstrored by Ohe et al. to constrict in response to hypoxia and removal of endothelium enhanced the hypoxia-induced vasoconstriction. Voltage gated Ca^{2+}
channels play a role in hypoxic vasoconstriction and pre stimulation is not a prerequisite [45].

Demiryurek et al. in their study on HPARs showed that hypoxia induced vasoconstriction in both smaller (0.38-0.68 mm) and larger (2.2 – 4.5 mm) diameter vessels under optimal resting conditions. This hypoxia-induced response is enhanced in both sizes HPARs when rings were pre constricted and removal of endothelium diminished the hypoxic vasoconstrictive response [44].

In contrary Ariyaratnam et al. demonstrated that larger HPARs (4 mm diameter) dilate in response to hypoxia and constrict when exposed to hyperoxia (95% O₂). This hypoxic vasodilation is independent to nitric oxide, because application of L-NAME had no effect. This study showed hypoxic vasoconstriction was reliant on voltage gated Ca²⁺ channels as evidenced by inhibition of vasoconstriction when HPARs treated with nifedipine (Ca²⁺ channel blocker) [99].

The reason of variation in response to different sized pulmonary vasculature to hypoxia and whether certain degree of pre stimulation is necessary is not clear. More studies need to be performed to confirm whether internal diameter of vessels and pre stimulation alters the reactivity of vessels to hypoxia.

SUMMARY AND CONCLUSION

Hypoxic pulmonary vasoconstriction is difficult to describe, as the underlying mechanism is complex. More than one mechanism contributes to the overall effect seen in clinical practice. So far most of the research was conducted on animals, which is not necessarily applicable on humans. In addition to this the reactivity of pulmonary vasculature to hypoxia varies between species. Even the experiments that are performed on human shows variability that may be due to variation in pulmonary vasculature reactivity to oxygen between healthy individuals and those who suffered from significant pulmonary disease [100, 101]. It is worth mentioning here that the definition of acute (5min – 12 hours) and chronic (2-7 days) hypoxia and the degree of hypoxia (0% O₂ – 5% O₂/5 – 30 mmHg) used for experiments on humans are variable which give rise to discrepancies. We need to agree on a universal definition for acute and chronic hypoxia and for degree of hypoxia to avoid such inconsistencies.

In conclusion the precise mechanism by which hypoxia stimulate pulmonary vasoconstriction has not been completely elucidated.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

I would like to thank Prof Saadeh Suleiman, Prof. Sarah George, Prof. Mahmoud Loubani and Prof. Alyn Morice for their support, supervision and constructive criticism.

REFERENCES


